Tema Heart & Health ETF HRTS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +10.15%
- 1 year
- +19.57%
- Open
- 39.03
- Prev close
- 38.20
- Mkt cap
- 57.04M
- Vol
- 2.58K
- Avg vol
- 2.36K
- EPS
- 1.37
- P/E
- 28.27
- Div yield
- 0.00%
More statistics
- Low
- 38.79
- High
- 39.03
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 32.41
- 200-d avg
- 33.09
5D chart
Signals (17)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 9:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:10 PM | 3 days ago |
| RSI: Oversold | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 5 days ago |
News
1 week ago zacks.com
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
1 month ago zacks.com
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
4 months ago zacks.com
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
4 months ago businesswire.com
Tema ETFs Exceeds $5bn in AUM After Three Years
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years…
4 months ago zacks.com
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
5 months ago benzinga.com
From Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.
5 months ago zacks.com
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
6 months ago businesswire.com
Tema ETFs Surpasses $2 Billion in AUM in Under Three Years
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced that the firm has surpassed $2 billion in assets under…
7 months ago benzinga.com
Why Is Eli Lilly Stock Gaining Today?
Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.
-
7 months ago benzinga.com
'Roche Restricts Consulting Work With Big Four Firms To Cut Costs' - Bloomberg
https://www.bloomberg.com/news/articles/2026-03-24/roche-restricts-consulting-work-with-big-four-firms-to-cut-costs?utm_source=latest&utm_medium=share&utm_campaign=copy
7 months ago benzinga.com
Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder
Ultragenyx Phase 3 gene therapy data shows reduced ammonia levels in rare disease patients, with further results expected in 2027.
8 months ago defenseworld.net
Tema Heart & Health ETF (NASDAQ:HRTS) Shares Down 1.5% – Time to Sell?
Tema Heart and Health ETF (NASDAQ: HRTS - Get Free Report) shares traded down 1.5% on Tuesday. The stock traded as low as $35.00 and last traded at $35.21. 6,130 shares traded hands during trading, a…
8 months ago businesswire.com
Tema Appoints ETF Industry Leader Steve Munroe as President
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this…
9 months ago etftrends.com
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This…
10 months ago defenseworld.net
Flow Traders U.S. LLC Has $522,000 Stock Holdings in Tema Heart & Health ETF $HRTS
Flow Traders U.S. LLC decreased its position in Tema Heart and Health ETF (NASDAQ: HRTS) by 67.6% during the undefined quarter, according to the company in its most recent filing with the SEC. The…
1 year ago etftrends.com
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance…
1 year ago etftrends.com
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends
2024 was an amazing year for investment performance, with the broad market S&P 500 TR Index up over 28%. There were also some serious ETF milestones achieved this year.
-
1 year ago benzinga.com
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.
1 year ago etftrends.com
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical…
2 years ago zacks.com
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.
2 years ago zacks.com
Tap the Weight-Loss Drug Market With These ETFs
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
2 years ago etftrends.com
Disruptive Theme of the Week: Playing Defense
When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.
2 years ago invezz.com
How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)
The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.
2 years ago seekingalpha.com
HRTS: Generating Alpha In Obesity Treatment
The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth…
2 years ago zacks.com
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug…